What is GLSI (GLSI) stock price today?

GLSI (GLSI) is currently trading at $15.01, up 0.4% today.

What is GLSI P/E ratio?

GLSI's P/E ratio is -21.98. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GLSI return on equity (ROE)?

GLSI's return on equity (ROE) is -533.33%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is GLSI's market cap?

GLSI has a market capitalization of $220.32M.

NASDAQ · Biotechnology

GLSI (GLSI) Stock

$15.01 +0.40% NASDAQ: GLSI Healthcare

Valuation

Metric	Value
Price	$15.01
Market Cap	$220.32M
P/E Ratio	-21.98
P/B Ratio	122.80
P/S Ratio	0.00
EPS (TTM)	$-1.21
52-Week High	$34.10
52-Week Low	$7.78
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-533.33%
ROA	-400.00%
ROCE	-800.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	2.00

Annual Financials (USD)

Metric	2020	2021	2022	2023	2024
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-2.0M	$-5.0M	$-8.0M	$-9.0M	$-16.0M
Net Profit	$-2.0M	$-5.0M	$-8.0M	$-9.0M	$-16.0M
EPS	$-0.15	$-0.35	$-0.61	$-0.69	$-1.21
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2020	2021	2022	2023	2024
Total Assets	$29.0M	$27.0M	$13.0M	$7.0M	$4.0M
Total Liabilities	$1.0M	$0	$0	$0	$2.0M
Cash	$29.0M	$27.0M	$13.0M	$7.0M	$4.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial MT Newswires · Jul 16, 2026 Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 GlobeNewswire · Jul 16, 2026 Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday MT Newswires · Jul 9, 2026 Sector Update: Healthcare MT Newswires · Jul 9, 2026 Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 GlobeNewswire · Jul 9, 2026

Cash Flow (USD)

Metric	2020	2021	2022	2023	2024
Operating Cash Flow	$-1.0M	$-4.0M	$-6.0M	$-6.0M	$-7.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$-8.0M	$0	$0
Net Cash Flow	$29.0M	$-1.0M	$-14.0M	$-6.0M	$-3.0M
Free Cash Flow	$-1.0M	$-4.0M	$-6.0M	$-6.0M	$-7.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-2.30%
Quick Ratio	2.35
Interest Coverage	—
Return 1Y	75.86%
Return 3Y	103.53%
Return 5Y	-54.65%

Ownership

Insiders Held47.86%

Institutions Held12.48%

Institutions Float Held23.93%

Institutional Holder	Shares	Report Date
Blackrock Inc.	433,860	2026-03-31
Vanguard Capital Management LLC	298,266	2026-03-31
Geode Capital Management, LLC	155,466	2026-03-31
State Street Corporation	133,875	2026-03-31
Nuveen, LLC	88,717	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AGEN	$7.99	+4.99%	3.04	$332.72M	0.00%
ATOS	$2.42	-3.20%	-1.23	$24.14M	0.00%
CGTX	$1.01	-1.94%	-3.94	$90.39M	0.00%
HURA	$2.03	-4.69%	-3.75	$129.28M	0.00%
IMMX	$14.01	-0.14%	-9.96	$762.17M	0.00%

About GLSI

GLSI is led by CEO Snehal S. Patel, employs 4 people, headquartered in US, publicly traded since 2020.

GLSI stock trades at $15.01 with a market capitalization of $220.32M. The stock is valued at a price-to-earnings (P/E) ratio of -21.98, price-to-book of 122.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.78 and $34.10, and currently trades 56.0% below its 52-week high.

On profitability, GLSI generates a return on equity (ROE) of -533.33%, return on capital employed of -800.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides